Drug Profile
DIO 901
Alternative Names: DIO-901; Very Low Dose Glucagon; VLDGLatest Information Update: 30 Dec 2009
Price :
$50
*
At a glance
- Originator DiObex
- Class Antihyperglycaemics; Hormones; Peptides
- Mechanism of Action Glucagon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypoglycaemia
Most Recent Events
- 05 Feb 2009 Clinical development is ongoing in USA
- 18 Mar 2008 DiObex and Camurus sign a license agreement to develop DIO 901 in an ER formulation using FluidCrystal® delivery technology for Hypoglycaemia
- 29 Jun 2007 Data presented at the 67th Scientific Sessions of the American Diabetes Association (ADA-2007) added to the Metabolic disorders therapeutic trials section